Powered by
ANN ARBOR — The Ann Arbor-based biopharmaceutical startup RetroSense Therapeutics LLC announced that the United States Patent and Trademark Office has granted U.S. patent Application No. 11,036,629, entitled “Method for …
ANN ARBOR — The pharmaceutical startup RetroSense Therapeutics LLC Monday announced the first patient in a Phase I/IIa clinical trial of its lead drug candidate, RST-001. The drug is designed …
ANN ARBOR — RetroSense Therapeutics, a privately held, clinical-stage biopharmaceutical company, announced that it has secured $6 million in a Series B financing to further investigate the use of gene …
ANN ARBOR — The pharmaceutical startup RetroSense Therapeutics LLC said Monday that its Investigational New Drug application for its lead drug candidate, RST-001, has received clearance from the United States …
ANN ARBOR — RetroSense Therapeutics LLC, the Ann Arbor pharma startup, said it had been selected as a finalist for the Luis Villalobos Award, sponsored by the Angel Capital Association. …
ANN ARBOR — The privately held biopharmaceutical company RetroSense Therapeutics said Thursday it had raised $6 million in Series A financing to investigate the use of gene therapy and optogenetics …
ANN ARBOR — The Ann Arbor biopharmaceutical startup RetroSense Therapeutics announced a license agreement for exclusive, worldwide rights to Massachusetts General Hospital’s patent application entitled “Method for Augmenting Vision in …
ANN ARBOR — Ann Arbor-based RetroSense Therapeutics LLC said it had received “orphan drug” status from the federal Food and Drug Administration for its lead drug candidate, RST-001, intended to …